"Cyclic S-Oxides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D003499
|
| MeSH Number(s) |
D02.886.124 D03.661.493
|
| Concept/Terms |
Cyclic S-Oxides- Cyclic S-Oxides
- S-Oxides, Cyclic
- Heterocyclic S-Oxides
- Heterocyclic S Oxides
- S-Oxides, Heterocyclic
- Cyclic S Oxides
- Oxides, Cyclic S
- S Oxides, Cyclic
|
Below are MeSH descriptors whose meaning is more general than "Cyclic S-Oxides".
Below are MeSH descriptors whose meaning is more specific than "Cyclic S-Oxides".
This graph shows the total number of publications written about "Cyclic S-Oxides" by people in this website by year, and whether "Cyclic S-Oxides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclic S-Oxides" by people in Profiles.
-
What Have We Learned from Expedition III and EPOCH Trials? Perspective of the CTAD Task Force. J Prev Alzheimers Dis. 2018; 5(3):171-174.
-
Inhibition of gamma-secretase activity impedes uterine serous carcinoma growth in a human xenograft model. Gynecol Oncol. 2014 Jun; 133(3):607-15.
-
Stat3 inhibitor Stattic exhibits potent antitumor activity and induces chemo- and radio-sensitivity in nasopharyngeal carcinoma. PLoS One. 2013; 8(1):e54565.
-
APE1/Ref-1 regulates STAT3 transcriptional activity and APE1/Ref-1-STAT3 dual-targeting effectively inhibits pancreatic cancer cell survival. PLoS One. 2012; 7(10):e47462.
-
The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models. Mol Cancer Ther. 2012 Sep; 11(9):1999-2009.
-
The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: a potential mechanism of therapeutic resistance. Clin Cancer Res. 2010 Dec 15; 16(24):6060-70.
-
Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model. Cancer Res. 2010 Mar 15; 70(6):2476-84.
-
Down-regulation of the Notch pathway mediated by a gamma-secretase inhibitor induces anti-tumour effects in mouse models of T-cell leukaemia. Br J Pharmacol. 2009 Nov; 158(5):1183-95.
-
Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells. Cancer Res. 2009 Apr 01; 69(7):3060-8.
-
Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology. 2009 May; 136(5):1741-9.e6.